Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029554 | 1.00 | ALOX15 (0.41) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL2030704 | 0.86 | ALOX15 (0.54) | ALOX15KDM4EGAAMAPTPIM1 | |
| SCHEMBL29741328 | 0.78 | AAK1 (0.46) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL7185544 | 0.78 | HSP90AA1 (0.43) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL20094079 | 0.78 | AAK1 (0.46) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL13500619 | 0.78 | HSP90AA1 (0.43) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL7185539 | 0.78 | HSP90AA1 (0.43) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL20096321 | 0.78 | AAK1 (0.46) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL21293969 | 0.78 | AAK1 (0.46) | ALOX15HSP90AA1KDM4EGAAMAPT | |
| SCHEMBL16311212 | 0.77 | ALOX15 (0.39) | ALOX15KDM4EGAAMAPTIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | IRAK1, IRAK2, IRAK3 | ALOX15 2687/4885HSP90AA1 1911/4885KDM4E 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.